查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1494853

2030 年胜胜肽治疗市场预测：按类型、给药途径、製造商类型、分子类型、技术、应用、最终用户和地区进行的全球分析

Peptide Therapeutics Market Forecasts to 2030 - Global Analysis By Type (Branded, Generic, Innovative and Other Types), Route of Administration, Manufacturer Type, Molecule Type, Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2024 年全球胜胜肽治疗市场规模为 491.5 亿美元，预计预测期内年复合成长率为 7.63%，到 2030 年将达到 764.1 亿美元。

胜肽疗法是一类令人兴奋的新型药物，它利用胜肽（短链氨基酸）来靶向和改变特定的生理途径。它们具有卓越的选择性和作用于多种生物标的（包括荷尔蒙、酵素和受体）的能力，使得这些治疗方法特别有用。当将新治疗方法与旧的小分子药物进行比较时，这种精确度可以开发出副作用较少的治疗方法。此外，利用创新方法治疗糖尿病、癌症和细菌感染等疾病，胜肽疗法已应用于肿瘤学、内分泌学和感染疾病等医学专业。

据美国糖尿病协会称，胜肽疗法是糖尿病治疗的重要进步，与传统治疗方法相比，可以改善血糖控制并减少副作用。

慢性病增加

糖尿病、癌症、心臟病和神经系统疾病等慢性病在全球的盛行率不断上升，推动了对更复杂治疗方法的需求。胜肽疗法由于能够精确靶向患病细胞和途径，因此为传统疗法提供了一个有前景的替代方案。例如，GLP-1受体促效剂是胜肽药物，对糖尿病患者的血糖控制具有优异的效果。此外，胜肽治疗市场受到慢性病患者数量不断增加的推动，导致对更安全、更有效的治疗的需求增加。

製造成本增加

胜胜肽治疗药物是使用昂贵且复杂的合成技术製造的，例如重组 DNA 技术和固相胜胜肽合成 (SPPS)。这些程序需要昂贵的机械、高度纯化的试剂和严格的品管程序，以确保所需产品的纯度和效力。此外，从实验室生产扩大到商业规模可能会令人望而却步。由于製造成本高昂，这些产品最终价格昂贵，这可能会限制可负担性和可用性，特别是在医疗保健预算紧张的开发中国家。

新兴市场的成长

胜肽疗法在新兴市场有巨大的成长空间，特别是在亚太地区、拉丁美洲和非洲。这些地区的医疗保健成本不断增加，慢性病发病率上升，医疗基础设施不断进步。改善获得尖端医疗保健的机会是这些地区政府和医疗保健组织的首要任务。透过正确进入这些市场，公司可以接触到庞大且不断扩大的患者群体。此外，与当地医疗保健提供者合作并符合当地监管要求可以顺利进入和拓展新市场。

生物製药与小分子药物的激烈竞争

胜肽疗法的市场竞争对手包括知名的小分子药物和生技药品。小分子药物因其保存期限长、生物有效性和製造成本低而通常受到青睐。基因治疗和单株抗体等生物製药因其高特异性和有效性而被广泛用于治疗多种慢性和复杂疾病。此外，由于这些替代品已确立的市场地位，胜肽疗法很难起步。为了在竞争中取得成功，产品必须在有效性、安全性、便利性等方面与竞争对手显着不同。

COVID-19 的影响：

胜肽治疗市场受到COVID-19大流行的多种影响，既阻碍又加速了该行业的成长。由于供应链中断和对抗疫情的医疗保健资金的重新分配，研究和生产能力暂时受到阻碍。然而，对高效药物和疫苗的迫切需求使人们对基于胜胜肽的治疗方法的潜力产生了关注，从而导致相关产品的资金增加并加速了监管核准。此外，疫情也引起了人们对创新药物输送方法和强大供应链重要性的关注，引发了最终可能服务于市场的发展和调整。

预计创新领域将在预测期内成为最大的领域

胜肽治疗市场由创新领域主导。这一优势是由创新胜胜肽药物研发的进步所推动的，这些药物为多种疾病提供标靶治疗方法，包括糖尿病、心血管疾病和癌症。新型胜胜肽通常被设计为具有高选择性、有效性和安全性，填补医学领域的空白并提供比现有治疗方法更好的治疗选择。此外，该市场的成长是由大量的研发支出以及对创新治疗的监管支持所推动的。

预计口腔细分市场在预测期间内年复合成长率最高

在胜胜肽治疗市场中，口服製剂领域预计将以最高的年复合成长率成长。迄今为止，胜肽药物由于生物有效性低且易在消化器官系统中被酶分解而难以口服给药。然而，药物传递技术的新发展，例如防止胜胜肽分解和改善吸收的口服製剂的开发，正在改变这种状况。此外，肠溶衣、酵素抑制剂和奈米颗粒载体等创新使口服胜胜肽疗法更具吸引力和可行性。

比例最高的地区：

胜肽治疗市场由北美主导。这项优势由多种因素支撑，包括强大的研发基础、慢性病的高盛行率以及有利的法律规范。该地区重要的製药和生物技术公司以及注重创新和技术进步的公司为该地区的主导地位做出了贡献。此外，患者和医疗保健提供者对胜肽疗法益处的认知不断提高，对个人化治疗和精准医疗的投资不断增加，正在推动北美市场的成长。

年复合成长率最高的地区：

胜肽治疗市场预计将见证亚太地区最高的年复合成长率。生物製药行业的成长、慢性病的流行、医疗保健成本的上升以及研发支出的增加推动了成长。中国、印度、日本和韩国正在成为全球製药业的主要参与者，并专注于开发胜胜肽药物等新型治疗方法。此外，由于积极的政府措施、改善的医疗基础设施和庞大的患者数量，亚太地区具有巨大的市场扩张潜力。

免费客製化服务

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和年复合成长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第1章执行摘要

第2章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 研究资讯来源
    • 主要研究资讯来源
    • 二次研究资讯来源
    • 先决条件

第3章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 技术分析
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • COVID-19 的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第5章全球胜胜肽治疗市场：依类型

  • 品牌
  • 非专利的
  • 创新的
  • 其他类型

第6章全球胜胜肽治疗药物市场：依给药途径

  • 胃肠外的
  • 口服
  • 黏膜
  • 注射
  • 鼻腔
  • 其他给药途径

第7章全球胜胜肽治疗市场：依製造商类型

  • 公司内部
  • CMO
  • 其他製造商类型

第8章全球胜胜肽治疗市场：依分子类型

  • 加压素
  • 生长抑制素
  • 利钠剂
  • 黄体激素(LH) 释放激素 (LHRH)
  • 胰岛素
  • 免疫胜胜肽
  • 升糖素及其类似物
  • 抑钙素
  • 其他分子类型

第9章全球胜胜肽治疗市场：依技术分类

  • 固相胜胜肽合成（SPPS）
  • 液相胜肽合成（LPPS）
  • 混合技术
  • 其他技术

第10章全球胜胜肽治疗市场：依应用分类

  • 代谢紊乱
  • 癌症
  • 心血管疾病
  • 胃肠道疾病
  • 中枢神经系统疾病
  • 感染疾病
  • 呼吸系统疾病
  • 疼痛管理
  • 租赁障碍
  • 皮肤科
  • 其他用途

第11章全球胜胜肽治疗市场：依最终用户分类

  • 製药和生物技术产业
  • 医院
  • 受託研究机构
  • 学术研究所
  • 其他最终用户

第12章全球胜胜肽治疗市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第13章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第14章 公司概况

  • Eli Lilly & Company
  • AstraZeneca PLC
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Pfizer Inc.
  • Bausch Health Companies Inc
  • Ever Neuro Pharma GmbH
  • AbbVie, Inc.
  • Ironwood Pharmaceuticals Inc.
  • Sanofi SA
  • Novo Nordisk A/S
  • Takeda Pharmaceutical Company Limited
  • Amgen Inc.
  • GlaxoSmithKline plc
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
Product Code: SMRC26372

According to Stratistics MRC, the Global Peptide Therapeutics Market is accounted for $49.15 billion in 2024 and is expected to reach $76.41 billion by 2030 growing at a CAGR of 7.63% during the forecast period. Peptide therapeutics are a new and exciting class of pharmaceuticals that target and modify particular physiological pathways by using peptides, which are short chains of amino acids. With their exceptional selectivity and capacity to engage with a wide variety of biological targets, such as hormones, enzymes, and receptors, these treatments are particularly useful. Comparing new treatments to older small-molecule medications, this precision allows for the development of therapies with fewer side effects. Moreover, utilizing innovative methods to treat ailments like diabetes, cancer, and bacterial infections, peptide therapeutics are used in oncology, endocrinology, and infectious diseases, among other medical specialties.

According to the American Diabetes Association, peptide therapeutics represent a significant advancement in the treatment of diabetes, offering improved glucose control and reduced side effects compared to conventional therapies.

Market Dynamics:

Driver:

Growing rate of chronic illnesses

The increasing prevalence of chronic illnesses worldwide, including diabetes, cancer, heart disease, and neurological disorders, is driving up demand for more sophisticated treatment alternatives. Peptide therapeutics presents a promising substitute for conventional therapies because of their capacity to precisely target diseased cells and pathways. GLP-1 receptor agonists, for example, are peptide medications that have demonstrated superior efficacy in glycemic control in diabetes. Furthermore, the market for peptide therapeutics is being driven by the increasing number of patients with chronic conditions, which is driving the demand for safer and more effective treatments.

Restraint:

Elevated production expenses

Peptide therapeutics is made using costly and intricate synthesis techniques like recombinant DNA technology and solid-phase peptide synthesis (SPPS). To guarantee the desired product's purity and effectiveness, these procedures call for expensive machinery, high-purity reagents, and stringent quality control procedures. Additionally, it can be unaffordable to scale up production from a laboratory to a commercial scale. Because of their high production costs, these products end up being more expensive, which can restrict their affordability and accessibility, particularly in developing nations where healthcare budgets are tight.

Opportunity:

Growth in emerging markets

Peptide therapeutics has a lot of room to grow in emerging markets, especially in Asia-Pacific, Latin America, and Africa. These areas are seeing increases in the cost of healthcare, a rise in the incidence of chronic illnesses, and advancements in the infrastructure of healthcare. Improving access to cutting-edge medical treatments is the main priority for these regions' governments and healthcare institutions. Companies can access a sizable and expanding patient population by judiciously entering these markets. Furthermore, smoother entry and expansion into new markets can be facilitated by working with regional healthcare providers and adjusting to local regulatory requirements.

Threat:

Fierce rivalry between biologics and small molecules

Market competitors for peptide therapeutics include well-known small-molecule medications and biologics. Because of their longer shelf life, oral bioavailability, and lower production costs, small-molecule drugs are typically preferred. Biologics are widely used in the treatment of a wide range of chronic and complex diseases because they have high specificity and efficacy, such as gene therapies and monoclonal antibodies. Moreover, peptide therapies have a difficult time taking off due to the established market positions of these alternatives; in order to successfully compete, they must significantly differ from the competition in terms of efficacy, safety, or convenience.

Covid-19 Impact:

The peptide therapeutics market was affected by the COVID-19 pandemic in a variety of ways, which both hampered and accelerated the industry's growth. Research and production capacities were momentarily hampered by supply chain disruptions and the reallocation of healthcare funds to pandemic management. But the pressing need for efficient medications and vaccines brought peptide-based therapies' potential to light, resulting in more funding and quicker regulatory approvals for related goods. Additionally, the pandemic also brought attention to the significance of creative drug delivery methods and robust supply chains, which sparked developments and adjustments that might eventually help the market.

The Innovative segment is expected to be the largest during the forecast period

The market for peptide therapeutics is dominated by the innovative segment. This dominance is fueled by the ongoing research and development of innovative peptide medications, which provide focused therapies for a variety of illnesses, such as diabetes, cardiovascular disease, and cancer. Novel peptides are generally engineered to possess heightened selectivity, effectiveness, and safety characteristics, filling gaps in the medical field and providing better therapeutic alternatives than established therapies. Furthermore, growth in this market has been driven by significant R&D expenditures as well as regulatory support for innovative treatments.

The Oral segment is expected to have the highest CAGR during the forecast period

In the peptide therapeutics market, the oral segment is anticipated to grow at the highest CAGR. Peptide medications have historically had difficulty being administered orally because of their low bioavailability and vulnerability to enzymatic breakdown in the gastrointestinal system. But new developments in drug delivery technologies are changing this, like the creation of oral formulations that prevent peptides from degrading and improve their absorption. Moreover, enteric coatings, enzyme inhibitors, and nanoparticle carriers are some of the innovations that are making oral peptide therapeutics more appealing and feasible.

Region with largest share:

The market for peptide therapeutics is dominated by North America. Numerous factors, such as a strong research and development base, a high incidence of chronic illnesses, and advantageous regulatory frameworks, are responsible for this dominance. Contributing to the region's leading position are important pharmaceutical and biotechnology companies, as well as a strong emphasis on innovation and technological advancements. Additionally, growing patient and healthcare professional awareness of the advantages of peptide therapeutics, along with rising investments in personalized therapies and precision medicine, are driving market growth in North America.

Region with highest CAGR:

The peptide therapeutics market is expected to grow at the highest CAGR in the Asia-Pacific area. The biopharmaceutical industry is growing, chronic disease prevalence is rising, healthcare costs are rising, and R&D spending is rising, among other factors driving this growth. China, India, Japan, and South Korea are becoming major players in the global pharmaceutical industry, focusing on the development of novel treatments such as peptide drugs. Furthermore, the Asia-Pacific region offers substantial prospects for market expansion due to favourable government initiatives, improving healthcare infrastructure, and a sizable patient population.

Key players in the market

Some of the key players in Peptide Therapeutics market include Eli Lilly & Company, AstraZeneca PLC, F. Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc., Bausch Health Companies Inc, Ever Neuro Pharma GmbH, AbbVie, Inc., Ironwood Pharmaceuticals Inc., Sanofi SA, Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, Amgen Inc., GlaxoSmithKline plc, Sun Pharmaceutical Industries Ltd. And Teva Pharmaceutical Industries Ltd.

Key Developments:

In May 2024, AstraZeneca has entered a worldwide licence and option agreement with Nona Biosciences for a preclinical monoclonal antibody. The deal focuses on the development of the antibody to develop targeted tumour therapies.

In January 2024, Roche and MOMA Therapeutics have signed a strategic partnership and licencing agreement for discovering drug targets for cancer. Under the alliance, Roche will obtain access to MOMA's KnowledgeBase platform to identify and prosecute new drug targets that are involved in the growth and survival of cancer cells.

In October 2023, French biotech company Mablink has entered an agreement to be acquired by Eli Lilly. The deal is subject to approval from the French Ministry of the Economy. Lilly plans to utilise Mablink's PSARLink technology, which disguises cancer-killing molecules, allowing them to be delivered precisely to cancer cells while sparing healthy cells. The technology will broaden the use of antibody-drug conjugates (ADCs).

Types Covered:

  • Branded
  • Generic
  • Innovative
  • Other Types

Route of Administrations Covered:

  • Parenteral
  • Oral
  • Mucosal
  • Injection
  • Nasal
  • Other Routes of Administrations

Manufacturer Types Covered:

  • In-house
  • CMO
  • Other Manufacturer Types

Molecule Types Covered:

  • Vasopressin
  • Somatostatin
  • Natriuretic
  • Luteinizing Hormone (LH)-Releasing Hormone (LHRH)
  • Insulins
  • Immunopeptide
  • Glucagon and Analogs
  • Calcitonin
  • Other Molecule Types

Technologies Covered:

  • Solid Phase Peptide Synthesis (SPPS)
  • Liquid Phase Peptide Synthesis (LPPS)
  • Hybrid Technology
  • Other Technologies

Applications Covered:

  • Metabolic Disorders
  • Cancer
  • Cardiovascular Disorders
  • Gastrointestinal Disorders
  • Central Nervous System Disorders
  • Infectious Diseases
  • Respiratory Disorders
  • Pain Management
  • Rental Disorders
  • Dermatology
  • Other Applications

End Users Covered:

  • Pharmaceutical and Biotechnology Industries
  • Hospitals
  • Contract Research Organization
  • Academic and Research Institutes
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Peptide Therapeutics Market, By Type

  • 5.1 Introduction
  • 5.2 Branded
  • 5.3 Generic
  • 5.4 Innovative
  • 5.5 Other Types

6 Global Peptide Therapeutics Market, By Route of Administration

  • 6.1 Introduction
  • 6.2 Parenteral
  • 6.3 Oral
  • 6.4 Mucosal
  • 6.5 Injection
  • 6.6 Nasal
  • 6.7 Other Routes of Administrations

7 Global Peptide Therapeutics Market, By Manufacturer Type

  • 7.1 Introduction
  • 7.2 In-house
  • 7.3 CMO
  • 7.4 Other Manufacturer Types

8 Global Peptide Therapeutics Market, By Molecule Type

  • 8.1 Introduction
  • 8.2 Vasopressin
  • 8.3 Somatostatin
  • 8.4 Natriuretic
  • 8.5 Luteinizing Hormone (LH)-Releasing Hormone (LHRH)
  • 8.6 Insulins
  • 8.7 Immunopeptide
  • 8.8 Glucagon and Analogs
  • 8.9 Calcitonin
  • 8.10 Other Molecule Types

9 Global Peptide Therapeutics Market, By Technology

  • 9.1 Introduction
  • 9.2 Solid Phase Peptide Synthesis (SPPS)
  • 9.3 Liquid Phase Peptide Synthesis (LPPS)
  • 9.4 Hybrid Technology
  • 9.5 Other Technologies

10 Global Peptide Therapeutics Market, By Application

  • 10.1 Introduction
  • 10.2 Metabolic Disorders
  • 10.3 Cancer
  • 10.4 Cardiovascular Disorders
  • 10.5 Gastrointestinal Disorders
  • 10.6 Central Nervous System Disorders
  • 10.7 Infectious Diseases
  • 10.8 Respiratory Disorders
  • 10.9 Pain Management
  • 10.10 Rental Disorders
  • 10.11 Dermatology
  • 10.12 Other Applications

11 Global Peptide Therapeutics Market, By End User

  • 11.1 Introduction
  • 11.2 Pharmaceutical and Biotechnology Industries
  • 11.3 Hospitals
  • 11.4 Contract Research Organization
  • 11.5 Academic and Research Institutes
  • 11.6 Other End Users

12 Global Peptide Therapeutics Market, By Geography

  • 12.1 Introduction
  • 12.2 North America
    • 12.2.1 US
    • 12.2.2 Canada
    • 12.2.3 Mexico
  • 12.3 Europe
    • 12.3.1 Germany
    • 12.3.2 UK
    • 12.3.3 Italy
    • 12.3.4 France
    • 12.3.5 Spain
    • 12.3.6 Rest of Europe
  • 12.4 Asia Pacific
    • 12.4.1 Japan
    • 12.4.2 China
    • 12.4.3 India
    • 12.4.4 Australia
    • 12.4.5 New Zealand
    • 12.4.6 South Korea
    • 12.4.7 Rest of Asia Pacific
  • 12.5 South America
    • 12.5.1 Argentina
    • 12.5.2 Brazil
    • 12.5.3 Chile
    • 12.5.4 Rest of South America
  • 12.6 Middle East & Africa
    • 12.6.1 Saudi Arabia
    • 12.6.2 UAE
    • 12.6.3 Qatar
    • 12.6.4 South Africa
    • 12.6.5 Rest of Middle East & Africa

13 Key Developments

  • 13.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 13.2 Acquisitions & Mergers
  • 13.3 New Product Launch
  • 13.4 Expansions
  • 13.5 Other Key Strategies

14 Company Profiling

  • 14.1 Eli Lilly & Company
  • 14.2 AstraZeneca PLC
  • 14.3 F. Hoffmann-La Roche Ltd.
  • 14.4 Novartis AG
  • 14.5 Pfizer Inc.
  • 14.6 Bausch Health Companies Inc
  • 14.7 Ever Neuro Pharma GmbH
  • 14.8 AbbVie, Inc.
  • 14.9 Ironwood Pharmaceuticals Inc.
  • 14.10 Sanofi SA
  • 14.11 Novo Nordisk A/S
  • 14.12 Takeda Pharmaceutical Company Limited
  • 14.13 Amgen Inc.
  • 14.14 GlaxoSmithKline plc
  • 14.15 Sun Pharmaceutical Industries Ltd.
  • 14.16 Teva Pharmaceutical Industries Ltd.

List of Tables

  • Table 1 Global Peptide Therapeutics Market Outlook, By Region (2022-2030) ($MN)
  • Table 2 Global Peptide Therapeutics Market Outlook, By Type (2022-2030) ($MN)
  • Table 3 Global Peptide Therapeutics Market Outlook, By Branded (2022-2030) ($MN)
  • Table 4 Global Peptide Therapeutics Market Outlook, By Generic (2022-2030) ($MN)
  • Table 5 Global Peptide Therapeutics Market Outlook, By Innovative (2022-2030) ($MN)
  • Table 6 Global Peptide Therapeutics Market Outlook, By Other Types (2022-2030) ($MN)
  • Table 7 Global Peptide Therapeutics Market Outlook, By Route of Administration (2022-2030) ($MN)
  • Table 8 Global Peptide Therapeutics Market Outlook, By Parenteral (2022-2030) ($MN)
  • Table 9 Global Peptide Therapeutics Market Outlook, By Oral (2022-2030) ($MN)
  • Table 10 Global Peptide Therapeutics Market Outlook, By Mucosal (2022-2030) ($MN)
  • Table 11 Global Peptide Therapeutics Market Outlook, By Injection (2022-2030) ($MN)
  • Table 12 Global Peptide Therapeutics Market Outlook, By Nasal (2022-2030) ($MN)
  • Table 13 Global Peptide Therapeutics Market Outlook, By Other Routes of Administrations (2022-2030) ($MN)
  • Table 14 Global Peptide Therapeutics Market Outlook, By Manufacturer Type (2022-2030) ($MN)
  • Table 15 Global Peptide Therapeutics Market Outlook, By In-house (2022-2030) ($MN)
  • Table 16 Global Peptide Therapeutics Market Outlook, By CMO (2022-2030) ($MN)
  • Table 17 Global Peptide Therapeutics Market Outlook, By Other Manufacturer Types (2022-2030) ($MN)
  • Table 18 Global Peptide Therapeutics Market Outlook, By Molecule Type (2022-2030) ($MN)
  • Table 19 Global Peptide Therapeutics Market Outlook, By Vasopressin (2022-2030) ($MN)
  • Table 20 Global Peptide Therapeutics Market Outlook, By Somatostatin (2022-2030) ($MN)
  • Table 21 Global Peptide Therapeutics Market Outlook, By Natriuretic (2022-2030) ($MN)
  • Table 22 Global Peptide Therapeutics Market Outlook, By Luteinizing Hormone (LH)-Releasing Hormone (LHRH) (2022-2030) ($MN)
  • Table 23 Global Peptide Therapeutics Market Outlook, By Insulins (2022-2030) ($MN)
  • Table 24 Global Peptide Therapeutics Market Outlook, By Immunopeptide (2022-2030) ($MN)
  • Table 25 Global Peptide Therapeutics Market Outlook, By Glucagon and Analogs (2022-2030) ($MN)
  • Table 26 Global Peptide Therapeutics Market Outlook, By Calcitonin (2022-2030) ($MN)
  • Table 27 Global Peptide Therapeutics Market Outlook, By Other Molecule Types (2022-2030) ($MN)
  • Table 28 Global Peptide Therapeutics Market Outlook, By Technology (2022-2030) ($MN)
  • Table 29 Global Peptide Therapeutics Market Outlook, By Solid Phase Peptide Synthesis (SPPS) (2022-2030) ($MN)
  • Table 30 Global Peptide Therapeutics Market Outlook, By Liquid Phase Peptide Synthesis (LPPS) (2022-2030) ($MN)
  • Table 31 Global Peptide Therapeutics Market Outlook, By Hybrid Technology (2022-2030) ($MN)
  • Table 32 Global Peptide Therapeutics Market Outlook, By Other Technologies (2022-2030) ($MN)
  • Table 33 Global Peptide Therapeutics Market Outlook, By Application (2022-2030) ($MN)
  • Table 34 Global Peptide Therapeutics Market Outlook, By Metabolic Disorders (2022-2030) ($MN)
  • Table 35 Global Peptide Therapeutics Market Outlook, By Cancer (2022-2030) ($MN)
  • Table 36 Global Peptide Therapeutics Market Outlook, By Cardiovascular Disorders (2022-2030) ($MN)
  • Table 37 Global Peptide Therapeutics Market Outlook, By Gastrointestinal Disorders (2022-2030) ($MN)
  • Table 38 Global Peptide Therapeutics Market Outlook, By Central Nervous System Disorders (2022-2030) ($MN)
  • Table 39 Global Peptide Therapeutics Market Outlook, By Infectious Diseases (2022-2030) ($MN)
  • Table 40 Global Peptide Therapeutics Market Outlook, By Respiratory Disorders (2022-2030) ($MN)
  • Table 41 Global Peptide Therapeutics Market Outlook, By Pain Management (2022-2030) ($MN)
  • Table 42 Global Peptide Therapeutics Market Outlook, By Rental Disorders (2022-2030) ($MN)
  • Table 43 Global Peptide Therapeutics Market Outlook, By Dermatology (2022-2030) ($MN)
  • Table 44 Global Peptide Therapeutics Market Outlook, By Other Applications (2022-2030) ($MN)
  • Table 45 Global Peptide Therapeutics Market Outlook, By End User (2022-2030) ($MN)
  • Table 46 Global Peptide Therapeutics Market Outlook, By Pharmaceutical and Biotechnology Industries (2022-2030) ($MN)
  • Table 47 Global Peptide Therapeutics Market Outlook, By Hospitals (2022-2030) ($MN)
  • Table 48 Global Peptide Therapeutics Market Outlook, By Contract Research Organization (2022-2030) ($MN)
  • Table 49 Global Peptide Therapeutics Market Outlook, By Academic and Research Institutes (2022-2030) ($MN)
  • Table 50 Global Peptide Therapeutics Market Outlook, By Other End Users (2022-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.